Nasal nitric oxide combined with clinical features for preliminary screening of primary ciliary dyskinesia in bronchiectasis - PubMed
3 days ago
- #nasal nitric oxide
- #bronchiectasis screening
- #primary ciliary dyskinesia
- A cross-sectional study used nasal nitric oxide (nNO) and clinical features to screen for primary ciliary dyskinesia (PCD) in 373 bronchiectasis patients, identifying PCD in 7.4%.
- nNO demonstrated high screening accuracy with 84.8% sensitivity and 97.1% specificity, combined with clinical features for effective preliminary PCD detection.
- PCD patients had more severe disease, including younger age, earlier bronchiectasis onset, lower lung function (FEV1, FVC), lower BMI, and strong associations with rhinosinusitis and Pseudomonas aeruginosa infection.
- Genetic analysis identified DNAH11 as the most common pathogenic gene in PCD patients, with 25.9% exhibiting situs inversus.
- The study reinforces the need for structured PCD screening in bronchiectasis populations using nNO and clinical features as a reliable strategy.